Clinical Trials Browser

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02137759 2023-05-06

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Phase 2 Unknown

29 enrolled

CNS

Glioblastoma

NCT00865969 2021-10-29

PTCL

Phase 2 Completed

129 enrolled 12 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00993616 2019-07-23

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Phase 2 Completed

29 enrolled 9 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

NCT01686165 2018-08-28

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

Phase 2 Completed

5 enrolled 8 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell

NCT00301756 2018-08-20

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

Phase 2 Completed

32 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00365053 2018-06-07

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Phase 2 Completed

13 enrolled 7 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00357032 2018-04-17

PXD101 in Treating Patients With Acute Myeloid Leukemia

Phase 2 Completed

12 enrolled 6 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT00589290 2015-09-30

Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage

Phase 2 Completed

41 enrolled 8 charts

Thoracic

Mediastinal Neoplasms, Thymoma

NCT00873119 2015-07-28

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Phase 2 Completed

89 enrolled 12 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00131261 2015-07-08

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

Phase 2 Completed

25 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT00431340 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Phase 2 Terminated

4 enrolled

Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms, Neoplasms, Plasma Cell

NCT00303953 2014-05-12

PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Completed

22 enrolled 8 charts

Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

PTCL

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

PXD101 in Treating Patients With Acute Myeloid Leukemia

Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma